Home›Trial›NCT07104383
NCT07104383Phase 3ACTIVE NOT RECRUITING

VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

Study Summary

This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight

Conditions
Weight Loss
Interventions / Drugs
VK2735
View on ClinicalTrials.gov ↗
Sponsor
VKTX
Viking Therapeutics
Metabolic Disease
C64/100
Study Details
Enrollment1100 participants
Primary Completion—
Lead SponsorViking Therapeutics, Inc.
Data Retrieved2026-04-11 04:31:01.273908+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 3 trials are pivotal studies with large patient populations (hundreds to thousands) designed to prove efficacy and safety for FDA submission. A successful Phase 3 readout is typically the last major hurdle before a New Drug Application (NDA) or BLA filing.

Status & Expected Data

Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.

Enrolled: 1,100 participants
Sponsor Catalyst Profile

Viking Therapeutics (VKTX) is the sponsoring company for this trial. BiotechSign currently grades this company C (64/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

VKTX Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.